Equities research analysts expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to announce $3.08 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Kala Pharmaceuticals’ earnings, with the highest sales estimate coming in at $4.27 million and the lowest estimate coming in at $2.50 million. The company is scheduled to announce its next earnings results on Monday, March 9th.
According to Zacks, analysts expect that Kala Pharmaceuticals will report full year sales of $7.99 million for the current financial year, with estimates ranging from $7.40 million to $9.17 million. For the next fiscal year, analysts anticipate that the business will report sales of $29.61 million, with estimates ranging from $17.16 million to $46.39 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.01). The company had revenue of $1.45 million during the quarter, compared to analyst estimates of $3.56 million.
Several equities analysts have recently commented on the company. Zacks Investment Research cut Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 19th. Wedbush reissued an “outperform” rating and set a $51.00 price target on shares of Kala Pharmaceuticals in a research report on Wednesday, August 7th. Oppenheimer set a $9.00 price target on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target (down from $12.00) on shares of Kala Pharmaceuticals in a report on Monday, November 11th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $17.85.
Large investors have recently bought and sold shares of the stock. Bank of Montreal Can grew its position in shares of Kala Pharmaceuticals by 148.5% in the 2nd quarter. Bank of Montreal Can now owns 4,014 shares of the company’s stock worth $26,000 after acquiring an additional 2,399 shares in the last quarter. Greenwich Wealth Management LLC lifted its stake in Kala Pharmaceuticals by 28.7% during the second quarter. Greenwich Wealth Management LLC now owns 13,000 shares of the company’s stock worth $83,000 after purchasing an additional 2,900 shares during the last quarter. Boston Partners boosted its holdings in Kala Pharmaceuticals by 4.7% in the third quarter. Boston Partners now owns 124,034 shares of the company’s stock worth $472,000 after purchasing an additional 5,603 shares during the period. Parametric Portfolio Associates LLC raised its holdings in shares of Kala Pharmaceuticals by 17.1% during the second quarter. Parametric Portfolio Associates LLC now owns 39,692 shares of the company’s stock worth $253,000 after purchasing an additional 5,806 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Kala Pharmaceuticals by 4.9% in the 2nd quarter. Northern Trust Corp now owns 198,260 shares of the company’s stock valued at $1,265,000 after buying an additional 9,183 shares during the period. Institutional investors and hedge funds own 64.21% of the company’s stock.
KALA stock traded down $0.12 during midday trading on Friday, hitting $4.02. 5,195 shares of the company’s stock were exchanged, compared to its average volume of 237,514. The company has a current ratio of 6.25, a quick ratio of 5.94 and a debt-to-equity ratio of 1.65. Kala Pharmaceuticals has a 12-month low of $3.24 and a 12-month high of $9.25. The firm has a 50 day moving average price of $3.81 and a 200-day moving average price of $4.74. The stock has a market capitalization of $144.72 million, a price-to-earnings ratio of -1.64 and a beta of 2.21.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Featured Story: What is the S&P 500 Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.